BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 26970916)

  • 1. Do incident and recurrent venous thromboembolism risks truly differ between heterozygous and homozygous Factor V Leiden carriers? A retrospective cohort study.
    Perez Botero J; Ormsby WD; Ashrani AA; McBane RD; Wysokinski WE; Patnaik MM; Lewis BR; Grill DE; Pruthi RK; Heit JA
    Eur J Intern Med; 2016 May; 30():77-81. PubMed ID: 26970916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.
    De Stefano V; Martinelli I; Mannucci PM; Paciaroni K; Chiusolo P; Casorelli I; Rossi E; Leone G
    N Engl J Med; 1999 Sep; 341(11):801-6. PubMed ID: 10477778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies.
    Marchiori A; Mosena L; Prins MH; Prandoni P
    Haematologica; 2007 Aug; 92(8):1107-14. PubMed ID: 17650440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FV Leiden mutation and risk of recurrent venous thromboembolism in Serbian population.
    Kovac M; Mikovic D; Antonijevic N; Rakicevic L; Djordjevic V; Radojkovic D; Elezovic I
    J Thromb Thrombolysis; 2008 Jun; 25(3):284-7. PubMed ID: 17549437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A.
    Lijfering WM; Middeldorp S; Veeger NJ; Hamulyák K; Prins MH; Büller HR; van der Meer J
    Circulation; 2010 Apr; 121(15):1706-12. PubMed ID: 20368522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism.
    Eichinger S; Weltermann A; Mannhalter C; Minar E; Bialonczyk C; Hirschl M; Schönauer V; Lechner K; Kyrle PA
    Arch Intern Med; 2002 Nov; 162(20):2357-60. PubMed ID: 12418950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High risk of thrombosis recurrence in patients with homozygous and compound heterozygous factor V R506Q (Factor V Leiden) and prothrombin G20210A.
    Federici EH; Al-Mondhiry H
    Thromb Res; 2019 Oct; 182():75-78. PubMed ID: 31472339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the Vienna Cancer And Thrombosis Study (CATS).
    Pabinger I; Ay C; Dunkler D; Thaler J; Reitter EM; Marosi C; Zielinski C; Mannhalter C
    J Thromb Haemost; 2015 Jan; 13(1):17-22. PubMed ID: 25381723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
    Emmerich J; Rosendaal FR; Cattaneo M; Margaglione M; De Stefano V; Cumming T; Arruda V; Hillarp A; Reny JL
    Thromb Haemost; 2001 Sep; 86(3):809-16. PubMed ID: 11583312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is recurrent venous thromboembolism more frequent in homozygous patients for the factor V Leiden mutation than in heterozygous patients?
    Procare Group
    Blood Coagul Fibrinolysis; 2003 Sep; 14(6):523-9. PubMed ID: 12960604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia.
    Martinelli I; Legnani C; Bucciarelli P; Grandone E; De Stefano V; Mannucci PM
    Thromb Haemost; 2001 Sep; 86(3):800-3. PubMed ID: 11583310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation.
    Tzoran I; Papadakis M; Brenner B; Fidalgo Á; Rivas A; Wells PS; Gavín O; Adarraga MD; Moustafa F; Monreal M;
    Am J Med; 2017 Apr; 130(4):482.e1-482.e9. PubMed ID: 27986523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of thrombophilic genes mutations on thrombosis risk in Egyptian nonmetastatic cancer patients.
    Wahba MA; Ismail MA; Saad AA; Habashy DM; Hafeez ZM; Boshnak NH
    Blood Coagul Fibrinolysis; 2015 Apr; 26(3):309-15. PubMed ID: 25565385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of the 4600A/G and 4678G/C polymorphisms in the endothelial protein C receptor (EPCR) gene on the risk of venous thromboembolism in carriers of factor V Leiden.
    Medina P; Navarro S; Estellés A; Vayá A; Bertina RM; España F
    Thromb Haemost; 2005 Aug; 94(2):389-94. PubMed ID: 16113830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activator inhibitor-1 4G/5G polymorphism, factor V Leiden, prothrombin mutations and the risk of VTE recurrence.
    Sundquist K; Wang X; Svensson PJ; Sundquist J; Hedelius A; Larsson Lönn S; Zöller B; Memon AA
    Thromb Haemost; 2015 Nov; 114(6):1156-64. PubMed ID: 26245493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homozygous factor V Leiden and double heterozygosity for factor V Leiden and prothrombin mutation.
    Saemundsson Y; Sveinsdottir SV; Svantesson H; Svensson PJ
    J Thromb Thrombolysis; 2013 Oct; 36(3):324-31. PubMed ID: 23054468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous thrombotic risk in family members of unselected individuals with factor V Leiden.
    Lensen RP; Bertina RM; de Ronde H; Vandenbroucke JP; Rosendaal FR
    Thromb Haemost; 2000 Jun; 83(6):817-21. PubMed ID: 10896231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis.
    Eckman MH; Singh SK; Erban JK; Kao G
    Med Decis Making; 2002; 22(2):108-24. PubMed ID: 11958494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
    Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
    Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.
    Eichinger S; Pabinger I; Stümpflen A; Hirschl M; Bialonczyk C; Schneider B; Mannhalter C; Minar E; Lechner K; Kyrle PA
    Thromb Haemost; 1997 Apr; 77(4):624-8. PubMed ID: 9134632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.